Executive Management

Stephen F. Betz, Ph.D., is a co-founder of Crinetics and was Vice President of Biology from December 2009 to October 2021 and currently serves as our Chief Scientific Officer. In addition, Dr. Betz is a Board Observer of Radionetics Oncology, a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for oncology indications, as well as Loyal for Dogs, a biotech startup developing drugs to increase dog healthspan.

Earlier in his career, Dr. Betz was Director of Endocrinology and Metabolism at Neurocrine Biosciences, Inc., where he worked on the discovery and development of GnRH receptor antagonists and nonpeptide modulators of other endocrine targets. Prior to Neurocrine, from 2001 to 2003, he led laboratory efforts at GeneFormatics, Inc., and from 1996 to 2000, he worked in pharmaceutical discovery at Abbott Laboratories, including structure-guided drug design, assay development, and compound screening in the Research Nuclear Magnetic Resonance Group.